China SXT Pharmaceuticals annual stock-based compensation
2022
2023
2024
2025
2026
China SXT Pharmaceuticals Stock-Based Compensation Growth & History (SXTC)
China SXT Pharmaceuticals's stock-based compensation was $5.3M for fiscal 2026.
View full China SXT Pharmaceuticals company overviewChina SXT Pharmaceuticals annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $5.3M | $5.3M | — |
| 2025 | 2025-03-31 | $0 | −$352,100 | — |
| 2024 | 2024-03-31 | $352,100 | −$202,471 | −36.51% |
| 2023 | 2023-03-31 | $554,571 | −$1.8M | −76.24% |
| 2022 | 2022-03-31 | $2.3M | — | — |
China SXT Pharmaceuticals stock-based compensation trends
Between the periods ended 2022-03-31 and 2026-03-31, China SXT Pharmaceuticals's stock-based compensation increased from $2.3M to $5.3M, a change of $3.0M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review China SXT Pharmaceuticals source filings ↗